Xavier Ruiz

Dr. Xavier Ruiz

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2010 in BJU International
Verified
Journal Article
Closed access
PDF file
EPEnrique Pieras
Enrique Pieras
GFGuillermo Frontera
Guillermo Frontera
XRXavier Ruiz
Xavier Ruiz
AVAntoni Vicens
Antoni Vicens
MOMariano Ozonas
Mariano Ozonas
PPPedro Pizá
Pedro Pizá

11 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
XRXavier Ruiz
Xavier Ruiz
AAAntonio Altuna-Coy
Antonio Altuna-Coy
MAMarta Alves-Santiago
Marta Alves-Santiago
JVJosé Vila-Barja
José Vila-Barja
JGJoan Francesc García-Fontgivell
Joan Francesc García-Fontgivell
Matilde R. ChacónMatilde R. Chacón
Matilde R. Chacón
Liquid biopsy-based biomarkers, including microRNAs packaged within extracellular vesicles, are promising tools for patient management. The cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is related to PCa progression and is found in the semen of patients with PCa. TWEAK can induce the transfer of exo-oncomiRNAs from tumor cells to body fluids, and this process might have utility in non-invasive PCa prognosis. We investigated TWEAK-regulated exo-microRNAs in semen and in post-digital rectal examination urine from patients with different degrees of PCa aggressiveness. We first identified 14 exo-oncomiRNAs regulated by TWEAK in PCa cells in vitro, and subsequently validated those using liquid biopsies from 97 patients with PCa. Exo-oncomiR-221-3p, -222-3p and -31-5p were significantly higher in the semen of high-risk patients than in low-risk peers, whereas exo-oncomiR-193-3p and -423-5p were significantly lower in paired samples of post-digital rectal examination urine. A panel of semen biomarkers comprising exo-oncomiR-221-3p, -222-3p and TWEAK was designed that could correctly classify 87.5% of patients with aggressive PCa, with 85.7% specificity and 76.9% sensitivity with an area under the curve of 0.857. We additionally found that TWEAK modulated two exo-oncomiR-221-3p targets, TCF12 and NLK. Overall, we show that liquid biopsy detection of TWEAK-regulated exo-oncomiRNAs can improve PCa prognosis prediction.

1 May 2013 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
CBC.R. Bonarriba
C.R. Bonarriba
JBJ.P. Burgués
J.P. Burgués
VVV. Vidaña
V. Vidaña
XRXavier Ruiz
Xavier Ruiz
PPP. Pizá
P. Pizá

9 September 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XRXavier Ruiz
Xavier Ruiz
EREsther Rodríguez-Gallego
Esther Rodríguez-Gallego
MAMarta Alves
Marta Alves
AAAntonio Altuna-Coy
Antonio Altuna-Coy
JLJavier Lozano-Bartolomé
Javier Lozano-Bartolomé
Matilde R. ChacónMatilde R. Chacón
Matilde R. Chacón
Background: Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of PCa aggressiveness.Methods: We collected biofluid samples (plasma/serum/semen/post-prostatic massage urine) from 98 patients that had undergone radical prostatectomy. Clinical biochemistry was performed and several cytokines/chemokines including soluble(s) TWEAK, sFn14, sCD163, sCXCL5 and sCCL7 were quantified by ELISA in selected biofluids. Also, the expression ofKLK2,KLK3,Fn14,CD163,CXCR2andCCR3was quantified by real-time PCR in semen cell sediment. Univariate, logistic regression, and receiver operating characteristic (ROC) analyses were used to assess the predictive ability of the selected biomarker panel in conjunction with clinical and metabolic variables for the evaluation of PCa aggressiveness.Results: Total serum levels of prostate-specific antigen (PSA), semen levels of sTWEAK, fasting glycemia and mRNA levels ofFn14,KLK2,CXCR2andCCR3in semen cell sediment constituted a panel of markers that was significantly different between patients with less aggressive tumors [International Society of Urological Pathology (ISUP) grade I and II] and those with more aggressive tumors (ISUP grade III, IV and V). ROC curve analysis showed that this panel could be used to correctly classify tumor aggressiveness in 90.9% of patients. Area under the curve (AUC) analysis revealed that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782–1] than a classical non-invasive selected clinical panel comprising age, tumor clinical stage (T-classification) and total serum PSA (AUC = 0.721 95% CI 0.613–0.830).Conclusions: TWEAK/Fn14 axis in combination with a selected non-invasive biomarker panel, including conventional clinical biochemistry, can improve the predictive power of serum PSA levels and could be used to classify PCa aggressiveness.

13 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
NPNahuel Paesano
Nahuel Paesano
XRXavier Ruiz
Xavier Ruiz
JAJOSE MARIA ABASCAL
JOSE MARIA ABASCAL
The primary objective of this study was to analyse the current accuracy of targeted and systematic prostate biopsies in detecting csPCa. A secondary objective was to determine whether there are factors predicting the finding of csPCa in targeted biopsies and, if so, to explore the utility of a predictive model for csPCa detection only in targeted biopsies. We analysed 2122 men with suspected PCa, serum PSA > 3 ng/mL, and/or a suspicious digital rectal examination (DRE), who underwent targeted and systematic biopsies between 2021 and 2022. CsPCa (grade group 2 or higher) was detected in 1026 men (48.4%). Discrepancies in csPCa detection in targeted and systematic biopsies were observed in 49.6%, with 13.9% of csPCa cases being detected only in systematic biopsies and 35.7% only in targeted biopsies. A predictive model for csPCa detection only in targeted biopsies was developed from the independent predictors age (years), prostate volume (mL), PI-RADS score (3 to 5), mpMRI Tesla (1.5 vs. 3.0), TRUS-MRI fusion image technique (cognitive vs. software), and prostate biopsy route (transrectal vs. transperineal). The csPCa discrimination ability of targeted biopsies showed an AUC of 0.741 (95% CI 0.721–0.762). The avoidance rate of systematic prostate biopsies went from 0.5% without missing csPCa to 18.3% missing 4.6% of csPCa cases. We conclude that the csPCa diagnostic accuracy of targeted biopsies is higher than that of systematic biopsies. However, a significant rate of csPCa remains detected only in systematic biopsies. A predictive model for the partial omission of systematic biopsies was developed.

23 October 2024 in Life
Verified
Journal Article
Open access
PDF file
JMJuan Morote
Juan Morote
NPNahuel Paesano
Nahuel Paesano
NPNatàlia Picola
Natàlia Picola
JMJesús Muñoz-Rodriguez
Jesús Muñoz-Rodriguez
XRXavier Ruiz
Xavier Ruiz
EHEnrique Trilla Herrera
Enrique Trilla Herrera
The role of digital rectal examination (DRE) in the early detection of significant prostate cancer (PCa) is being questioned in the era of magnetic resonance imaging (MRI). However, some men with suspected PCa may still be identified solely through DRE, even with low serum prostate-specific antigen (PSA) levels. Additionally, most predictive models designed to improve significant PCa diagnostic pathways incorporate DRE findings. We assessed the role of DRE among 5005 men with serum PSA levels > 3.0 ng/mL and/or suspicious DRE findings, who underwent pre-biopsy MRI and targeted and/or systematic biopsies, as part of the significant PCa opportunistic screening program in Catalonia (Spain) between 2016 and 2023. Significant PCa, defined as grade group > 2, was detected in 2097 men (41.9%). Suspicion of PCa was based solely on DRE in 206 cases (4.1%) with significant PCa detected in 50 of them (2.4%). Two pathways using the Barcelona predictive models, before and after MRI, with and without DRE findings showed specificities of 52.8 and 38.7%, respectively (p < 0.001), after fixing sensitivity at 90%. Prostate biopsy was avoided in 35.1 and 26.7%, respectively (p < 0.001), while its efficacy increased from 52.8 to 58%. We conclude that DRE improved the effectiveness of an opportunistic significant PCa-screening program.